New heart failure drug MK-2828 put through drug interaction test

NCT ID NCT07431866

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial in 41 healthy adults tested whether multiple doses of MK-2828, a potential heart failure treatment, affect how the body processes rosuvastatin and furosemide. The goal was to check for drug interactions that could impact future dosing. The study provides early safety and interaction data but does not test MK-2828's effectiveness for heart failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MK-2828

What this could lead to

If successful, this study could help determine safe dosing of MK-2828 alongside common heart failure medications.

What could go wrong

This is an early-stage drug interaction study in healthy people, not a treatment trial. Results may not predict effectiveness or safety in heart failure patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fortrea Clinical Research Unit Inc ( Site 0001)

    Daytona Beach, Florida, 32117, United States